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Comprehensive analysis of The 
Cancer Genome Atlas reveals 
a unique gene and non-coding 
RNA signature of fibrolamellar 
carcinoma
Timothy A. Dinh1,2,3, Eva C. M. Vitucci3,4, Eliane Wauthier5,6, Rondell P. Graham7, 
Wendy A. Pitman3, Tsunekazu Oikawa5,6, Mengjie Chen3,8, Grace O. Silva3,6,9, 
Kevin G. Greene10, Michael S. Torbenson7, Lola M. Reid5,6 & Praveen Sethupathy1,3,6
Fibrolamellar carcinoma (FLC) is a unique liver cancer primarily affecting young adults and characterized 
by a fusion event between DNAJB1 and PRKACA. By analyzing RNA-sequencing data from The Cancer 
Genome Atlas (TCGA) for >9,100 tumors across ~30 cancer types, we show that the DNAJB1-PRKACA 
fusion is specific to FLCs. We demonstrate that FLC tumors (n = 6) exhibit distinct messenger RNA 
(mRNA) and long intergenic non-coding RNA (lincRNA) profiles compared to hepatocellular carcinoma 
(n = 263) and cholangiocarcinoma (n = 36), the two most common liver cancers. We also identify a set 
of mRNAs (n = 16) and lincRNAs (n = 4), including LINC00473, that distinguish FLC from ~25 other liver 
and non-liver cancer types. We confirm this unique FLC signature by analysis of two independent FLC 
cohorts (n = 20 and 34). Lastly, we validate the overexpression of one specific gene in the FLC signature, 
carbonic anhydrase XII (CA12), at the protein level by western blot and immunohistochemistry. Both 
the mRNA and lincRNA signatures support a major role for protein kinase A (PKA) signaling in shaping 
the FLC gene expression landscape, and present novel candidate FLC oncogenes that merit further 
investigation.
Fibrolamellar carcinoma (FLC) is a rare form of liver cancer, representing ~1% of known liver cancer cases, and 
primarily occurring in adolescents and young adults without any history of liver disease, steatosis, fibrosis, or cir-
rhosis1–4. Histologically, FLC is unique among liver tumors, as it is characterized by intratumoral lamellar bands 
of fibrosis, large polygonal cells, eosinophilic cytoplasm, prominent nucleoli, and reduced nuclear to cytoplasmic 
ratio1–3. Currently, no clinical biomarkers for FLC exist and the majority of patients have metastases at the time of 
diagnosis. Surgery is the first-line therapeutic for FLC, but tumors often recur even following resection5,6. Patients 
with inoperable tumors have very poor prognosis and currently no standard accepted chemotherapeutic regimen 
for FLC exists3,5,6.
In addition to histology, several other features distinguish FLC from other liver tumors. The average age of 
onset for FLC patients is ~25 compared to approximately 60 for hepatocellular carcinoma (HCC) and cholan-
giocarcinoma (CCA) patients1–3,5,7,8. While HCC and CCA predominantly affect males, FLC has a relatively 
balanced gender distribution1. FLC patients typically do not exhibit dramatically elevated levels of aspartate 
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aminotransferase (AST) or alanine aminotransferase (ALT), canonical markers of liver inflammation and necro-
sis1–3. In contrast, HCC commonly occurs in the context of long-standing cirrhosis often due to chronic hepatitis 
or alcoholic liver damage8. For this reason, FLC patients generally have more favorable survival compared to HCC 
and CCA patients. However, after controlling for the presence of cirrhosis, FLC and HCC patients have similar 
5-year survival rates9. Finally, recurrent mutations commonly found in HCC (e.g., TERT, TP53, CTNNB1) or CCA 
(e.g., KRAS, IDH1) have not been identified in FLC tumors2,3,10,11.
FLC tumors express markers of biliary and hepatocytic, (e.g. CK7, HepPar-1) as well as neuroendocrine 
(e.g. PCSK1, NTS) lineages3,11–15. We also have shown that FLCs are remarkably rich in cancer stem cells, unlike 
HCCs and CCAs, and that their gene expression profile more closely resembles that of primitive biliary tree 
stem cells than any other lineage stage of the liver16. Recently, a heterozygous ~400 kb deletion on chromosome 
19 was described in a study of 11 FLC patients17. This deletion was present in all FLC patient tumors, but not in 
adjacent non-tumor liver, and uniformly led to the chimeric transcript DNAJB1-PRKACA. This chimera swaps 
exon 1 of PRKACA, the catalytic subunit of protein kinase A (PKA), with exon 1 of DNAJB1, a heat shock protein 
of the HSP40 family. The DNAJB1-PRKACA transcript is translated into a fusion protein that retains PKA kinase 
activity13,17–19. Follow-up studies have detected this fusion in larger cohorts of FLC patients and have proposed 
that it may be a specific marker of FLC11,20.
Long intergenic non-coding RNA (lincRNA) is a class of non-coding RNAs longer than 200 nucleotides that 
do not code for protein and are key players in tumorigenesis21. Many lincRNAs are highly tissue and cell-type 
specific and have been shown to control proliferation and metastasis by their diverse cellular roles including 
transcriptional regulation, chromatin remodeling, intracellular protein localization, and competitive endogenous 
RNA activity21–25. Despite the growing appreciation for lincRNAs in cancer, they have not yet been examined in 
the context of FLC.
Recently, several groups have compared gene expression and mutation signatures of FLC tumors with that of 
adjacent non-tumor liver10,11,13,15,17. Other studies of specific genes have also revealed differences between FLC 
and HCC26–30. However, no study has yet characterized a molecular signature of FLC that distinguishes it from 
other liver cancers or other non-liver tumor types. Here, we identify six cases of FLC within The Cancer Genome 
Atlas (TCGA), half of which were originally classified as HCC. Transcriptomic analysis of FLCs reveals a unique 
messenger RNA (mRNA) and lincRNA signature of FLC. We confirm this signature in two independent valida-
tion cohorts of 20 and 34 FLC tumors. Most of the genes, and all of the lincRNAs, of the signature have not previ-
ously been specifically highlighted as markers of FLC, and therefore represent both novel markers and candidate 
oncogenes of FLC. A key finding is that many genes and lincRNAs in the FLC signature, including LINC00473, 
point to the likely importance of cyclic adenosine monophosphate (cAMP)-mediated PKA signaling in shaping 
FLC gene expression. We perform additional experimental validation for one member of the mRNA signature, 
carbonic anhydrase XII (CA12), which may have tumor and/or metastasis promoting functions. This work moti-
vates future experimental investigation to determine the role of FLC signature genes and lincRNAs, as well as 
DNAJB1-PRKACA, in FLC pathogenesis.
Results
Identification of FLC cases in TCGA. The fusion transcript DNAJB1-PRKACA is thought to be pres-
ent in almost all FLC cases11,17, but thus far has not been detected in any other type of liver cancer, leading 
to the hypothesis that DNAJB1-PRKACA is specific to FLC20. To evaluate this hypothesis, we analyzed RNA-
sequencing (RNA-seq) data from 9158 tumor and 692 non-tumor samples across 29 different cancer types in 
TCGA (Supplementary Table S1). We detected robust evidence for expression of DNAJB1-PRKACA in six sam-
ples, all of which were tumors classified as Liver Hepatocellular Carcinoma (LIHC, Fig. 1a). Interestingly, three 
of these samples were subannotated as FLC, whereas the other three were subannotated as HCC. To validate 
the fusion in each of the samples, we confirmed the presence of the heterozygous ~400 kb deletion by analy-
sis of whole exome sequencing (WES) data, single nucleotide polymorphism microarray (SNP array) data, or 
both (Supplementary Fig. S1). The three samples subannotated as HCC could be indicative of non-FLC tumors 
expressing DNAJB1-PRKACA (which has not been observed previously) or FLC tumors that were misannotated 
as HCCs (which was not uncommon historically). To distinguish between these two possibilities, we examined 
additional data sources available through TCGA for all six tumors expressing the chimera.
We first examined histology slides available for the six tumors expressing DNAJB1-PRKACA. Two liver 
pathologists (KGG, MST) independently reviewed all histology slides. The three samples annotated as FLC 
(TCGA-DD-A4NB, TCGA-RC-A6M5, TCGA-MR-A8JO) all showed classical features of this tumor type includ-
ing lamellar bands of fibrosis, eosinophilic cytoplasm, large nuclei, and prominent nucleoli. Of the three samples 
annotated as HCC, one displayed classical histological features of FLC (Fig. 1b, TCGA-5R-AA1D), while the 
other two exhibited histological features of both FLC and HCC (Fig. 1b, TCGA-RC-A6M3, TCGA-DD-A1EC). 
The percentage of reads overlapping the DNAJB1-PRKACA fusion junction and the percentage of paired reads 
encompassing the entire junction were not significantly different in the samples with classical FLC histology com-
pared to those with characteristics of both FLC and HCC morphology (Supplementary Fig. S1).
Due to the lack of access to the original tissues, we were not able to perform additional diagnostic staining of 
FLC protein markers (e.g., CD68, CK7) in order to further characterize the mixed FLC-HCC samples. However, 
we did analyze the expression of previously reported FLC RNA markers, PCSK113–15 and AGR227, and found 
that together they do differentiate the six DNAJB1-PRKACA expression tumors from all HCC and CCA samples 
(Supplementary Fig. S2).
We next examined the ages of the patients from which these six tumors were resected. The mean ages at diag-
nosis for annotated FLC and misannotated HCC patients were 26.33 (range of 20–34) and 20.33 (range of 17–24), 
respectively, both of which are consistent with the age of onset for FLC and significantly lower than that of HCC 
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and CCA (Fig. 1c, Supplementary Fig. S1). Taken together with our histological and RNA marker analyses, we 
conclude that all six tumor samples expressing DNAJB1-PRKACA display features consistent with FLC. We refer 
to these six as FLC going forward.
Identification of differentially expressed genes in FLC compared to HCC and CCA. To determine 
if the gene expression profiles of FLCs differ from that of other liver cancers, we performed hierarchical clustering 
of FLC (n = 6), HCC (n = 263), and CCA (n = 36) samples with TCGA RNA-seq data using the 10,000 most var-
iable genes across all samples. Our analysis revealed that the six FLCs clustered together in a clade separate from 
Figure 1. Identification of FLC samples in The Cancer Genome Atlas (TCGA). (a) Six FLC samples were 
identified in TCGA by RNA expression of DNAJB1-PRKACA. While all six samples were annotated as Liver 
Hepatocellular Carcinoma (LIHC), three were subannotated as FLC and 3 were subannotated as HCC. These 
three samples were examined further using whole exome sequencing, SNP array (to validate the chromosome 
19 deletion resulting in DNAJB1-PRKACA), histology, and patient ages. (b) Sample histology images from the 
three annotated FLC samples and three misannotated HCC samples, all of which express DNAJB1-PRKACA. 
Arrowheads depict intratumoral fibrotic bands and arrows depict distinct nuclei with prominent nucleoli 
characteristic of FLC tumor cells. (c) Density plot depicting the age distribution of annotated FLC, misannotated 
HCC, annotated HCC, and CCA patients in TCGA. Dotted lines represent the mean age of each group.
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all HCCs and CCAs (Fig. 2a), indicating that FLCs have a unique gene expression profile distinct from other liver 
cancers. Importantly, all six FLC tumors were sequenced in separate batches. This finding held true with the addi-
tion of non-tumor liver (n = 50) and cholangiocyte (n = 9) samples to the analysis (Supplementary Fig. S3). It is 
important to note that FLC tumor purity31,32 was well within the range observed for HCC (Supplemental Fig. S4), 
indicating that tumor purity alone cannot account for the clustering of FLC samples.
Next we sought to identify the genes significantly differentially expressed between FLC and both HCC and 
CCA. Genes were considered in the analysis if they had an average normalized count ≥ 50 in at least one tumor 
type, and were defined as differentially expressed if they exhibited > 2 fold-difference in average expression level 
and false discovery rate (FDR) < 0.05 between FLC and both HCC and CCA. We found 444 differentially expressed 
genes between FLC and HCC and 1509 between FLC and CCA. Of these, 163 were differentially expressed 
between FLC and both HCC and CCA with concordant directionality (Fig. 2b, Supplementary Table S2). As 
expected, hierarchical clustering of FLC, HCC, and CCA samples based on the expression of these 163 genes 
resulted in a dendrogram with a clade containing only the six FLC samples (Supplementary Fig. S5). Moreover, 
principal component analysis showed that these 163 genes distinguish FLC from each of 20 other non-liver can-
cer types for which gene expression data is available through TCGA (Supplementary Fig. S6), although there are 
some notable exceptions of specific papillary renal cell carcinoma tumor samples that cluster closely with the FLC 
cases (Supplementary Fig. S6i).
Gene ontology analysis of these 163 genes revealed a significant enrichment in transmembrane receptor pro-
tein kinase activity and growth factor binding (Fig. 2c). Furthermore, kinase enrichment analysis revealed that 
Figure 2. FLCs share a unique mRNA expression profile compared to other liver cancers. (a) Hierarchical 
clustering of FLC (n = 6), HCC (n = 263), and CCA (n = 36) samples in TCGA. Clustering was performed 
using the 10,000 most variable genes across all tumors following Variance Stabilizing Transformation with 
Euclidian distance and Ward’s minimum variance method. (b) Venn diagram showing differentially expressed 
genes between FLC and both HCC and CCA. Genes were defined as differentially expressed using the following 
criteria: average normalized counts ≥ 50 in at least one tumor type, fold change > 2, and FDR < 0.05. (c) Gene 
Ontology Molecular Function analysis of the 163 genes differentially expressed between FLC and both HCC 
and CCA. (d) Kinase Enrichment Analysis of the 163 genes differentially expressed between FLC and both 
HCC and CCA. (c,d) Show only results with at least 5 genes in each category. Dotted lines represent p = 0.05. 
PRKACA (protein kinase A catalytic subunit alpha), PRKCA (protein kinase C alpha).
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the 163 genes are most significantly over-represented for substrates of PRKACA, supporting the notion that 
wild-type PKA and/or DNAJB1-PRKACA may be critical to the etiology and molecular characteristics of FLC 
(Fig. 2d).
Determination of an FLC mRNA signature. We next sought to determine which among the 163 genes 
are most unique to FLC compared to HCC and CCA. Therefore, we identified the genes whose expression levels 
in all FLC samples are greater or less than 95% of all HCC and CCA samples. This analysis resulted in a set of 16 
genes, which we refer to as the FLC mRNA signature (Fig. 3). All 16 of these genes are up-regulated in FLC and 
also distinguish FLC tumors from non-malignant liver and non-malignant cholangiocytes (Fig. 3). We validated 
this FLC gene signature in two independent cohorts of FLC cases. Using RNA-seq data for 20 FLC tumors from 
Honeyman et al.17 we confirmed that 14 out of the 16 genes (except CREB3L1 and ITPRIP) are indeed signifi-
cantly elevated in FLC relative to HCC and CCA (Supplementary Fig. S7). Analysis of microarray data for 34 
FLC tumors from Cornella et al.11 demonstrated that most of these genes were significantly elevated in FLC 
compared to non-malignant liver tissue (Supplementary Fig. S8). Further analysis of the Cornella et al. dataset, 
in which the authors had provided evidence for three different FLC subtypes11, showed that several genes (e.g., 
CA12, NOVA1, PCSK1, TMEM163, and TNRC6C) are significantly elevated in FLC irrespective of the subtype 
(Supplementary Fig. S9).
CK7 and CD68 are currently used as protein markers to diagnose FLC3. However, CK7 protein is expressed 
in approximately 1/3 of conventional HCCs33 and CD68 is routinely expressed in macrophages located within 
Figure 3. Sixteen genes most uniquely distinguish FLC from other liver cancers. Boxplots depicting RNA 
levels of 16 genes in the FLC mRNA signature in FLC (n = 6), HCC (n = 263), CCA (n = 36), non-malignant 
liver (NML, n = 50), and non-malignant cholangiocyte/bile duct (NMC, n = 9) from TCGA. Y-axis shows 
counts normalized by DESeq. Shaded regions of boxplots show the 25th–75th quantiles of the data with the 
median denoted by a bold line. Whiskers of boxplots represent data < 25th and > 75th quantiles. Circles represent 
data points that are outliers, defined as points < 25th quantile minus 1.5*IQR (interquartile range, 75th–25th 
quantile) or > 75th quantile plus 1.5*IQR. *FDR < 0.05 (DESeq, negative binomial test) of FLC compared to both 
HCC and CCA.
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the sinusoids of conventional HCCs34. In fact, our analysis shows that at least at the RNA level, many HCCs and 
CCAs express both CD68 and CK7 at levels observed in FLCs (Supplementary Fig. S10). Furthermore, many 
other current and proposed markers of FLC3,13–15,26,27,30,35 do not seem to effectively distinguish between FLC and 
other liver cancers (Supplementary Fig. S11). Two genes in the 16-gene signature, protein convertase subtilisin/
kexin type 1 (PCSK1) and p21-activated kinase 3 (PAK3), were previously described as elevated in FLC by mul-
tiple studies13–15. Both PCSK136 and PAK337 have been reported as markers of neuroendocrine tumors and FLC 
tumors have been shown to display neuroendocrine characteristics13,14. However, notably, 14 out of the 16 genes 
in the signature have not been linked etiologically to FLC or specifically highlighted previously as biomarkers of 
FLC relative to other tumor types.
Analysis of the FLC mRNA signature across non-liver tumor types. We next sought to determine 
if these 16 genes could also distinguish FLC from other non-liver cancers. We found by analysis of RNA-seq 
data in TCGA, for 7211 tumor samples across 20 non-liver cancer types with available non-tumor tissue data 
(Supplementary Table S3), that 14 of the 16 genes are up-regulated to a greater extent in FLC relative to the cor-
responding adjacent non-malignant tissue than in any other tumor type (Fig. 4a). Also, among these 14 genes, 
eight are more abundant in FLC than in any other tumor type (Fig. 4a), indicating that these eight genes not only 
distinguish FLC from other liver tumors, but also likely uniquely mark FLC. These eight genes include ornithine 
aminotransferase (OAT) and solute carrier family 16 member 14 (SLC16A14), which are on average 6.4 and 7.0 
fold more highly expressed in FLC, respectively, than the tumor type with the next highest expression. Six of the 
14 genes are not uniquely elevated in FLC, such as neuro-oncological ventral antigen 1 (NOVA1) and carbonic 
anhydrase XII (CA12), but several of these have been described as candidate oncogenes in the context of other 
cancers. For example, NOVA1 overexpression leads to invasion and proliferation in HCC cell lines and is corre-
lated with poor prognosis in HCC patients38. CA12 regulates extracellular pH and is overexpressed in a subset 
of renal cell carcinomas and breast tumors39,40. Additionally, inhibition of CA12 and other carbonic anhydrase 
family members has been proposed as a cancer therapeutic41–43.
We also evaluated by RNA-seq the expression of the 16 genes in our previously described patient-derived 
xenograft (PDX) model of FLC, which is currently the only FLC disease model available, as well as in normal cells 
of four different maturational lineage stages of the liver: biliary tree stem cells (BTSC), hepatic stem cells (HpSC), 
hepatoblasts (HB), and adult hepatocytes (AHEP). We found that 15 of the 16 are dramatically up-regulated in 
the FLC PDX model compared to all of the other liver lineage stages, including BTSCs (Fig. 4b). Our previous 
work has suggested that BTSCs may be the cell type of origin for FLC tumors16. The finding that most genes in our 
FLC mRNA signature are elevated in the FLC PDX model compared to BTSCs suggests that they may also play a 
functional role in FLC pathogenesis.
Identification of differentially expressed long non-coding RNAs in FLC compared to HCC and 
CCA. LincRNAs play an important role in the biology of a wide array of different tumor types21, but have never 
previously been characterized in FLC. To determine if the lincRNA expression profile of FLCs differs from that 
of other liver cancers, we performed hierarchical clustering of FLC (n = 6), HCC (n = 263), and CCA (n = 36) 
samples with TCGA RNA-seq data using the 500 most variable lincRNAs across all samples. Our analysis revealed 
that the six FLCs clustered together in a clade separate from all HCCs and CCAs (Fig. 5a), indicating that FLCs 
have a unique lincRNA expression profile distinct from other liver cancers.
To identify specific lincRNAs that are differentially expressed in FLC compared to both HCC and CCA, 
we performed differential lincRNA expression analyses using DESeq. LincRNAs were defined as differentially 
expressed if they exhibited > 2 fold-difference in average expression level and FDR < 0.05 between FLC and both 
HCC and CCA. We found five differentially expressed lincRNAs between FLC and HCC and 47 between FLC and 
CCA. Of these, 4 were differentially expressed between FLC and both HCC and CCA with concordant direction-
ality (Fig. 5b, Supplementary Table S4).
Determination of an FLC lincRNA signature. We next sought to determine which among the 4 lincR-
NAs are most unique to FLC compared to HCC and CCA. Therefore, we identified the lincRNAs whose expres-
sion levels in all FLC samples are greater or less than 95% of all HCC and CCA samples. This analysis identified 
one lincRNA, RP11-157N3.1. When we relaxed the threshold from 95% to 90%, we identified a total of three 
lincRNAs (AF064858.6, LINC00313, RP11-157N3.1), which we refer to as the lincRNA signature (Fig. 5c). The 
robust up-regulation of these three lincRNAs in FLC relative to HCC was validated using an independent database 
of quantified lincRNAs called The Atlas of Non-coding RNAs in Cancer (TANRIC) (Supplementary Fig. S12). 
Interestingly, LINC00313 was previously annotated as the potential protein-coding gene C21orf84 and was iden-
tified as differentially expressed between FLC and both HCC and CCA in the mRNA analysis above (Fig. 2b, 
Supplementary Table S2). Additionally, we noticed that while another lincRNA, LINC00473, missed the threshold 
for significance, it was nevertheless notably overexpressed in FLC (Fig. 5c). LINC00473 (previously annotated as 
C6orf176) has been linked to cAMP-mediated gene regulation44–46. Since FLCs express a recurrent fusion protein 
containing the catalytic subunit of PKA and PKA is a cAMP-dependent protein kinase, LINC00473 may serve as 
a marker of aberrant cAMP levels or as a downstream effector of cAMP-mediated mechanisms.
Analysis of the FLC lincRNA signature across non-liver tumor types. We next sought to determine 
if these four lincRNAs could also distinguish FLC from other non-liver cancers. We found by analysis of data in 
the TANRIC database that all four of the lincRNAs are up-regulated to a greater extent in FLC relative to the cor-
responding adjacent non-malignant tissue than in any other tumor type (Fig. 5d). Furthermore, all four are more 
abundant in FLC than in any other tumor type (Fig. 5d), suggesting that these lincRNAs not only distinguish FLC 
from other liver tumors, but are also likely unique to FLC. Finally, we also evaluated by RNA-seq the expression 
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Figure 4. The FLC mRNA signature distinguishes FLC from non-liver cancers and normal liver 
maturational lineage stages. (a) Scatterplot where each point represents a different tumor type within TCGA 
(n = 22). FLC is shown in purple, HCC is shown in blue, and CCA is shown in green. All other tumor types 
are shown in black. The x-axis displays the average fold change for each tumor type relative to the appropriate 
non-tumor tissue and the y-axis displays the average RNA levels of each gene in each tumor type. (b) Heatmap 
showing the RNA expression of 16 genes in the FLC mRNA signature in a FLC patient-derived xenograft (PDX) 
model and four normal maturational lineage stages of the human liver: biliary tree stem cells (BTSC), hepatic 
stem cells (HpSC), hepatoblasts (HB), and adult hepatocytes (AHEP). Shown are n = 4 distinct passages of the 
FLC PDX model and n = 3 biological replicates for each liver lineage stage.
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Figure 5. FLCs share a unique lincRNA expression profile. (a) Hierarchical clustering of FLC (n = 6), 
HCC (n = 263), and CCA (n = 36) samples in TCGA. Clustering was performed using the 500 most variable 
lincRNAs across all tumors following Variance Stabilizing Transformation with Euclidian distance and Ward’s 
minimum variance method. (b) Venn diagram depicting differentially expressed lincRNAs between FLC and 
both HCC and CCA. Genes were defined as differentially expressed using the following criteria: fold change > 
2 and FDR < 0.05. (c) Boxplots depicting expression of the three members of the FLC lincRNA signature and 
LINC00473 in FLC, HCC, CCA, non-malignant liver (NML), and non-malignant cholangiocytes/bile duct 
(NMC) from TCGA. (d) Scatterplot of three members of the FLC lincRNA signature and LINC00473 where 
each point represents a different tumor type within TCGA (n = 14), with FLC marked in purple, HCC in blue, 
and all other tumor types in black. The x-axis displays the average fold change for each tumor type relative 
to the appropriate non-tumor tissue and the y-axis displays the average expression level of each lincRNA in 
each tumor type. (e) Heatmap showing the expression of three members of the FLC lincRNA signature and 
LINC00473 in a FLC patient-derived xenograft (PDX) model and four normal maturational lineage stages of the 
human liver: biliary tree stem cells (BTSC), hepatic stem cells (HpSC), hepatoblasts (HB), and adult hepatocytes 
(AHEP). *FDR < 0.05 (DESeq, negative binomial test) of FLC compared to both HCC and CCA.
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of the four lincRNAs in the FLC PDX model as well as in each of the four different maturational lineage stages of 
the liver mentioned above. Only the levels of LINC00313 and LINC00473 were significantly elevated in the FLC 
PDX model (Fig. 5e).
Validation of CA12 overexpression in FLC. Lastly, we aimed to provide comprehensive validation of one 
of the genes in the FLC signature. We selected CA12 for four reasons. First, CA12 upregulation has already been 
associated with other highly aggressive cancers, most notably specific subtypes of renal cell carcinoma and breast 
cancer39,40. Second, CA12 regulates extracellular pH, which plays a role in important cancer processes including 
invasion and metastasis. Third, consistent with the known functions of CA12, we observed substantially greater 
mRNA levels of CA12 in metastatic FLC tumors compared to primary FLC tumors in an independent dataset17 
(Fig. 6a). Fourth, PKA has been shown to phosphorylate CA9, a carbonic anhydrase in the same family as CA12 
with similar function and cellular localization47. Phosphorylation of CA9 modulates its activity, implicating PKA 
in tumor invasion in part by regulation of carbonic anhydrases and extracellular pH.
We first validated overexpression of CA12 in our FLC PDX model at the RNA and protein level compared to 
Huh7 cells, a human HCC cell line. RT-qPCR and western blot analyses showed significant upregulation of CA12 
RNA and protein expression, respectively, in FLC cells (Fig. 5b,c). Importantly, RT-qPCR detected the expres-
sion of DNAJB1-PRKACA transcripts in our FLC PDX model, but not in Huh7 cells (Supplementary Fig. S13). 
Immunohistochemistry (IHC) of cells from our FLC PDX model grown as spheroids and FLC xenografts showed 
dramatic upregulation of CA12 compared to normal liver (Fig. 5d). Additional IHC staining of primary samples 
revealed positive signal for CA12 in 12/12 FLC cases, but only 4/14 HCC tumors, and 0/5 normal liver samples 
(Fig. 5e,f).
Discussion
FLC is a rare liver cancer that primarily affects adolescents and young adults1. Previous genomic studies have 
primarily compared FLC tumors to adjacent non-tumor tissue10,11,13,15,17. However, global transcriptomic com-
parisons of FLC to multiple other liver cancers, or other non-liver tumor types, have not been examined. Here, 
through RNA-seq analyses of protein coding genes and lincRNAs in FLC, HCC, and CCA, as well as > 25 other 
tumor types, we identify a unique mRNA and lincRNA signature and candidate oncogenes in FLC.
Recently, multiple studies have confirmed the presence of a fusion transcript, DNAJB1-PRKACA, in FLC 
tumor samples11,13,16,17. This fusion has been proposed to be specific to FLC20. Examining nearly 10,000 samples, 
we have performed the most extensive analysis evaluating this hypothesis and find that DNAJB1-PRKACA is 
indeed specific to FLC tumors. This finding motivates further implementation of FLC diagnostics testing for the 
presence of this unique fusion. Although DNAJB1-PRKACA is present in the majority of FLC tumors, one group 
recently reported FLC tumors lacking the chimera11. It remains unclear if these tumors really lack the chimera, if 
the chimera is expressed at lower levels, or if these tumors are misclassified. If there is indeed a minority of FLC 
tumors without the fusion, further work is necessary to determine whether these cancers resemble the majority 
of FLC tumors at the transcriptomic level.
In our analyses, we detected robust evidence of DNAJB1-PRKACA expression in six tumor samples all clas-
sified as Liver Hepatocellular Carcinoma. Interestingly, three samples were subannotated as FLC, while three 
were subannotated as HCC. For these six samples, we confirmed the presence of the chromosome 19 deletion 
that results in the fusion transcript through WES or SNP array. The ages of all six patients (17–34) were also 
consistent with those previously reported for FLC patients (Supplementary Fig. S1). Evaluation of the single 
histology slide available for each tumor demonstrated that four tumors (three subannotated as FLC and one sub-
annotated as HCC) displayed classical FLC histology, while two tumors (both subannotated as HCC) displayed 
histological features of both FLC and HCC. Unfortunately, without access to these samples or additional histo-
logical images, we were unable to perform diagnostic stains or evaluation to further confirm the FLC diagnosis. 
Importantly, both samples with and without classical FLC histology showed similar evidence for the presence of 
the DNAJB1-PRKACA fusion transcript.
FLC tumors with regions of histology resembling HCC have previously been identified. Notably, in one case 
fluorescent in situ hybridization identified genomic PRKACA rearrangements throughout the tumor including 
the regions with HCC histology20. Previous work has also demonstrated that FLCs with classical histology have 
distinct gene expression signatures than FLCs with mixed histology14. While our results demonstrate that all 
six FLCs shared similar gene expression profiles, we did notice that the two FLC tumors with mixed histology 
consistently clustered together (data not shown), confirming the previous findings. While FLCs with mixed histo-
logical features have been previously described14,20, more work is necessary to determine whether these are truly 
distinct etiologically from FLCs with classical histology.
We identified 163 genes using DESeq that were differentially expressed in FLC compared to both HCC and 
CCA (Fig. 2b). These genes also distinguished FLC from 20 additional non-liver tumors (Supplementary Fig. S6). 
However, it is worth noting that we did identify a small subset of papillary renal cell carcinoma (KIRP) samples that 
displayed similar gene expression signatures to FLC and were enriched for type 2 KIRP tumors48. Interestingly, type 
2 KIRP tumors are highly aggressive like FLC and also share some very similar histological features with FLC includ-
ing large cells with eosinophilic cytoplasm and prominent nucleoli48. Gene ontology analysis of these genes revealed 
enrichment of multiple types of kinase activity and growth factor binding (Fig. 2c). Additionally, we performed 
kinase enrichment analysis49, which identifies enrichment for substrates, curated from multiple kinase-substrate 
resources, in a given gene set. Kinase enrichment analysis of these 163 genes demonstrated enrichment of PRKACA 
substrates (Fig. 2d) suggesting that PKA activity, likely though the DNAJB1-PRKACA fusion, distinguishes FLC 
from both HCC and CCA. Within this set of 163 genes, we identified 16 genes that most uniquely distinguished 
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Figure 6. Validation of aberrant CA12 upregulation in FLC. (a) CA12 RNA levels quantified by RNA-seq 
in non-tumor adjacent liver, primary FLC tumors, and metastatic FLC tumors in an independent cohort of 
FLC tumors17. (b) CA12 expression quantified by qRT-PCR in cultured spheroids from a FLC PDX model and 
Huh7, a human HCC cell line. CA12 expression was normalized to RPS9. Statistical significance determined by 
Student’s two-tailed t-test. Data shown are mean ± SD and display one representative experiment of biological 
replicates (n = 3 for Huh7, n = 6 for FLC PDX spheroids) of 4 total experiments. (c) CA12 expression measured 
by western blot in cultured spheroids from a FLC PDX model and Huh7. Uncropped blots are presented in 
Supplementary Fig. S14. (d) CA12 expression measured by immunohistochemistry in cultured spheroids from a 
FLC PDX model, xenograft tissue from a FLC PDX model, and normal human adult liver tissue. Magnification, 
40x (top right), 20x (rest). (e) CA12 expression measured by immunohistochemistry in primary FLC and HCC. 
Magnification, 20x. (f) Table showing summary of samples with CA12 positive staining by IHC. NML, non-
malignant liver. *p < 0.05, ****p < 0.0001 (Mann-Whitney U test).
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FLC from other liver cancers that we refer to as the FLC mRNA signature (Fig. 3). Notably, only 2 of the genes in the 
mRNA signature, PCSK1 and PAK3, have been previously described as markers of FLC13–15.
Apart from PCSK1 and PAK3, none of the remaining 14 genes have been explicitly linked to FLC. However, 
some of these have been shown to play important biological functions in other cancers. For example, NOVA1 
encodes for a RNA-binding protein that is associated with poor overall survival and increased recurrence in HCC 
patients. Overexpression of NOVA1 also increases HCC proliferation, invasion, and migration38. CA12 codes for 
a carbonic anhydrase responsible for regulating extracellular pH and is elevated in certain subsets of renal cell 
carcinoma and breast cancers39,40. Inhibition of CA12 enzymatic activity has also been proposed as a therapeutic 
strategy for breast cancer41–43. Additionally, some of the remaining genes in the FLC mRNA signature including, 
TMEM163, TNRC6C, and C10orf128 have yet to be extensively characterized in cancer. Future studies will be 
necessary to determine if they play a functional role in FLC biology.
We evaluated the expression of the 16 genes in the mRNA signature in 20 non-liver tumor types within 
TCGA and found that 14 of the 16 genes are more up-regulated in FLC relative to the corresponding adjacent 
non-malignant tissue than in any other tumor type (Fig. 4a). Among these 14 genes, eight are more abundant in 
FLC than in any other tumor type, demonstrating that these eight genes not only distinguish FLC from other liver 
tumors, but also likely uniquely mark FLC. Among these eight genes are OAT and SLC16A14. OAT, ornithine 
aminotransferase, is a mitochondrial protein that catalyzes the reversible formation of proline from ornithine. 
OAT is positively regulated by β -catenin and cAMP and inhibition of OAT in HCC suppresses proliferation50–52. 
SLC16A14 is a poorly characterized monocarboxylate transporter suggested to play a role in resistance to chemo-
therapy in ovarian cancer53.
Our previous work has demonstrated that FLCs are most similar to biliary tree stem cells (BTSCs) compared 
to three other maturational lineage stages of the liver based on gene expression profile16. These results suggest that 
BTSCs may be the cell type of origin for FLC tumors. Interestingly, FLC tumors do not cluster with cholangiocar-
cinomas (Fig. 2a), which are commonly thought to derive from normal biliary cells. Examination of the 16 genes 
in the mRNA signature in a unique FLC patient-derived xenograft (PDX) model and these four different lineage 
stages of the liver, including BTSCs, demonstrated upregulation of 15 genes in FLC compared to all other lineage 
stages (Fig. 4b).
Non-coding RNAs play a major role in many biological processes, including cancer initiation and progres-
sion21,24. However, non-coding RNAs have yet to be explored in the context of FLC. We decided to focus on long 
intergenic non-coding RNAs (lincRNAs), which have been shown to be important in proliferation and metastasis. 
Hierarchical clustering of FLC, HCC, and CCA samples based on the 500 most variable lincRNAs demonstrated 
that FLCs share a distinct lincRNA expression profile compared to other liver cancers (Fig. 5a). We identified 
four lincRNAs that were differentially expressed between FLC and both HCC and CCA (Fig. 5b) and found that 
three of these were more highly expressed in all FLC samples than 90% of the HCC and CCA samples (Fig. 5c). 
Additionally, we identified one lincRNA, LINC00473, which missed the significance threshold, but was still overex-
pressed in FLC. We refer to these four as the FLC lincRNA signature. Interestingly, LINC00473 expression is posi-
tively regulated by cAMP through PKA and has been suggested as a biomarker of deregulated cAMP signaling44,45. 
Very recently it was shown in non-small cell lung cancer (NSCLC) that LINC00473 is regulated by PKA/CREB, 
correlates with poor prognosis, and is required for tumor growth and survival. Our analysis confirms that 
LINC00473 is highly expressed in NSCLC; however, remarkably, the levels are 3-fold higher in FLC. These data 
indicate that the possibility of a mechanistic role for LINC00473 in FLC pathogenesis merits further investigation. 
The four lincRNAs in the signature also are more abundant in FLC than in multiple non-liver tumors as well as 
more overexpressed compared to adjacent non-tumor tissue in FLC than other tumor types (Fig. 5d). Evaluation 
of the lincRNA signature demonstrated overexpression of two lincRNAs, LINC00313 and LINC00473, in FLC 
compared to four lineage stages of the liver, including BTSCs, suggesting these two lincRNAs may play a role in 
FLC pathogenesis (Fig. 5e).
Finally, we validated overexpression of one gene in the FLC mRNA signature, CA12. At both the RNA and 
protein level, CA12 was upregulated in FLC compared to HCC and normal liver (Fig. 5). Interestingly, we also 
observed high CA12 expression in metastatic FLC tumors, consistent with previous reports suggesting that CA12 
and extracellular pH play an important role in metastasis40.
We have identified a signature of protein-coding genes and lincRNAs that distinguish FLC from ~22 other 
liver and non-liver cancers. Additional analysis has revealed that these genes are upregulated in FLCs compared 
to BTSCs, the potential FLC cell type of origin, suggesting that many of these genes may play a role in FLC 
pathogenesis. Functional evaluation of these genes will be necessary to dissect their role(s) in FLC. These genes 
also provide additional confirmatory evidence for the diagnosis of FLC. Whether these genes are upregulated 
in FLC independent of the DNAJB1-PRKACA fusion or as a result of it remains uncertain. In either situation, 
these genes may act to promote development and/or progression of FLC. If there do exist true FLCs lacking the 
DNAJB1-PRKACA fusion, it remains unclear if these genes are also upregulated in these tumors.
Overall, our results point to dysregulation of cAMP/PKA signaling as a major force shaping the gene 
expression landscape in FLC and also reveal additional genes that may play an important role in FLC etiology. 
Functional validation of the DNAJB1-PRKACA fusion and genes in the mRNA and lincRNA signature in the 
context of FLC may reveal novel therapeutic targets of this rare and deadly cancer.
Materials and Methods
RNA expression analysis. RNA-seq data for TCGA fusion (9840 samples—9148 tumor and 691 non-tu-
mor samples—across 29 annotated tumor types, Supplementary Table S1) and differential gene expression anal-
ysis (263 HCC, 6 FLC (both HCC and FLC are annotated as LIHC within TCGA), 50 non-tumor liver, 36 CCA, 
9 non-tumor bile duct/cholangiocytes) were downloaded from the Cancer Genomics Hub (CGHub). RNA-seq 
data for one FLC validation cohort (20 FLC, 9 non-malignant liver)17 were downloaded from the database of 
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Genotypes and Phenotypes (dbGaP, study accession phs000709.v1.p1). Microarray data for a second FLC vali-
dation cohort (34 FLC, 5 non-malignant liver)11 were downloaded from the Gene Expression Omnibus (GEO, 
GSE57725). RNA-seq data for the FLC PDX (patient-derived xenograft) model and liver lineages were previously 
described16 and are available on GEO (GSE73114). Normalized (quartile normalization) data for gene expression 
analysis across 20 non-liver tumors, LIHC, and CCA (8302 samples—7621 tumor and 681 non-tumor samples, 
Supplementary Table S3) were obtained from the TCGA Data Portal. Normalized (RPKM) data for lincRNA 
expression analysis across 13 non-liver tumors and LIHC (5367 samples—4803 tumor and 564 non-tumor sam-
ples, Supplementary Table S5) were obtained from The Atlas of non-coding RNA in cancer (TANRIC)54. Quality 
of FASTQ files was assessed using FastQC and reads were aligned to the human hg19 genome with MapSplice255. 
Transcripts were quantified using RSEM56 with 2011 UCSC Known Gene definitions for protein-coding genes 
and GENCODE release 19 for lincRNAs. Normalization and differential expression analysis for RNA-seq were 
performed using DESeq57. Genes were classified as differentially expressed if they met the following criteria: fold 
change ≥ 2, false discovery rate (FDR) < 0.05, and > 50 normalized counts in at least one tissue type. LincRNAs 
were classified as differentially expressed if they met the following criteria: fold change ≥ 2 and FDR < 0.05. 
Hierarchical clustering was performed in R using Euclidean distance and Ward’s minimum variance method fol-
lowing Variance Stabilizing Transformation provided by DESeq. Gene ontology and kinase enrichment analysis49  
was performed using Enrichr58. Differential expression for microarray data was performed using the Mann-
Whitney U test.
Copy number variation analysis. For whole exome sequencing analysis, 10 kb bin counts data were gen-
erated using BEDTools. The read ratios were calculated by using the count in tumor divided by the count in 
matched normal for each bin. A circular binary segmentation59 procedure with default parameters was applied 
to segment the genome. For SNP array analysis, publically available level 3 segmented copy number data for all 
TCGA LIHC Affymetrix 6.0 SNP arrays were downloaded through the Broad Institute’s TCGA GDAC Firehose 
data portal (http://gdac.broadinstitute.org/). We filtered for segments that included a copy number alteration 
on chromosome 19. Samples with a deletion at chr19:14239803-14624494 were identified by having a segment 
annotation (i.e. segment start and segment stop genomic position) that completely encompasses chr19:14239803-
14624494 and that also have a segment mean less than or equal to − 0.1.
Histology and patient ages. Histology images were accessed from the TCGA Data Portal and from the 
Cancer Digital Slide Archive60. Liver histology was reviewed independently by two gastrointestinal pathologists 
(KGG, MST). Ages of patients were obtained from TCGA using the R package TCGA2STAT61.
Cells. Cells from the patient-derived xenograft (PDX) model of FLC were grown in NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ or NOD scid gamma (NSG) immunocompromised mice, isolated, and cultured as previously 
described16. Procedures were performed according to protocols approved by the UNC School of Medicine at 
Chapel Hill IACUC. The mice were housed in UNC’s DLAM sterile facility in micro-isolated autoclaved cages 
with free access to autoclaved water and radiation sterilized food. Huh7 cells were obtained and cultured as pre-
viously described62.
Primary samples. 12 FFPE fibrolamellar carcinomas, 14 hepatocellular carcinomas, and 3 non-malignant 
livers were collected from the Mayo Clinic (Rochester, MN) institutional clinical archives. 2 additional 
non-malignant livers were obtained from human donors. The FLC samples were previously shown to harbor 
DNAJB1-PRKACA transcripts by qRT-PCR and were positive for a PRKACA rearrangement by FISH20. We have 
characterized these cases as morphologically typical fibrolamellar carcinomas and they were previously part of 
another study, which showed that FGFR1 was not amplified in fibrolamellar carcinoma63.
Quantitative real-time PCR. qRT-PCR was carried out as described previously62,64. Briefly, total RNA 
was extracted using the Total RNA Purification Kit (Norgen Biotek, Thorold, Ontario, Canada). Reverse 
Transcription was performed using the High Capacity RNA-to-cDNA Kit (Thermo Fischer Scientific, 
Waltham, MA). Gene expression was quantified with using TaqMan Gene Expression Assays (Thermo 
Fischer Scientific) on a CFX96 Touch Real-Time System (Bio-Rad, Hercules, CA). Assays were performed in 
triplicate. CA12 and DNAJB1-PRKACA mRNA expression levels were normalized to the housekeeping gene, 
RPS9. CA12 fold increase was calculated based on the 2−ΔΔCT method in comparison to Huh7 cells, a human 
HCC cell line. The Taqman assays used were CA12 (Assay ID Hs01080902_m1) and DNAJB1-PRKACA 
(custom assay, F: CGCAAGCGCGAGATCTTC, R: GAAAATCTTCTTTGGCTTTGGCTAAGA, Probe: 
CTTTCACTTCCTCCCCGTAGCG).
Western blotting. Huh7 cells and FLC PDX spheroids were lysed in lysis buffer (RIPA buffer (Sigma, St. 
Louis, MO), 25x Complete Protease Inhibitor Cocktail (Sigma), 100x Pierce Phosphatase Inhibitor (Thermo Fisher 
Scientific), 100 mM phenylmethanesulfonyl fluoride, β -mercaptoethanol, 1 M dithiothreitol) at 4 °C. All lysates were 
flash frozen, thawed, and centrifuged for 10 minutes at 14,000 × g at 4 °C. Protein concentration was quantified 
using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). Samples were diluted 1:1 in Laemmli Sample 
Buffer (Bio-Rad) containing 5% β -mercaptoethanol, heated at 95 °C for 3 minutes, loaded into 12% Mini-PROTEAN 
TGX Precast Gel (Bio-Rad), and run in 1X Tris/Glycine/SDS buffer (Bio-Rad) for 75 minutes at 150 V. Transfer was 
performed with the Trans-Blot Turbo Transfer System (Bio-Rad). Membranes were blocked with either 4% milk 
or bovine serum albumin (BSA), probed with primary mouse anti-CA12 (1:500, ab140385, Abcam, Cambridge, 
MA) or rabbit anti-vinculin (1:1000, #4650, Cell Signaling Technology, Danvers, MA), and then incubated with 
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horseradish peroxidase conjugated secondary antibodies. Membranes were incubated in ECL Prime Western 
Blotting Detection System (GE Healthcare, Little Chalfont, UK) for 5 minutes before visualization.
Immunohistochemistry. FLC xenograft tissue, FLC PDX spheroids, and non-malignant liver (n = 2) were 
fixed in 4% paraformaldehyde overnight and stored in 70% ethanol. Samples were paraffin embedded, cut into 
5 μ m sections, and deparaffinized. Antigen retrieval was performed by steaming tissue sections in 1x sodium 
citrate buffer, Citrate Plus (ScyTec, West Logan, UT) for 20 minutes. Endogenous peroxidase activity was blocked 
using 3% hydrogen peroxide diluted in TBS for 15 minutes at room temperature. Endogenous biotin activity 
was blocked using 2.5% Normal Horse Serum Blocking Solution (Vector Laboratories, Burlingame, CA) for 
1 hour at room temperature. Sections were incubated in primary mouse anti-CA12 (1:75, ab140385, Abcam), 
diluted in TBS, overnight at 4 °C. Sections were then incubated in secondary antibody, ImmPRESS™ REAGENT 
Anti-mouse Ig (Vector Laboratories, #MP-7402) at room temperature for 30 minutes. Chromogen staining was 
performed using ImmPACT DAB Peroxidase Kit (Vector Laboratories, #SK-4105). Sections were lightly counter-
stained using hematoxylin, dehydrated, mounted in xylene, and visualized. For primary FLC, primary HCC, and 
non-malignant liver (n = 3) samples, tissue sectioning and IHC staining was performed at the Pathology Research 
Core (Mayo Clinic, Rochester, MN) using the Leica Bond RX stainer (Leica, Buffalo, IL). Formalin Fixed Paraffin 
Embedded (FFPE) tissues were sectioned at 5 microns. The tissue slides were dewaxed and retrieved on-line using 
the following reagents: Bond Dewax (Leica) and Epitope Retrieval 2 (EDTA; Leica). Tissue slides were retrieved 
for 20 minutes. The primary mouse anti-CA12 (ab140385, Abcam) was used at 1:500 and it was incubated for 
15 minutes. The detection system used was Polymer Refine Detection System (Leica). This system includes the 
hydrogen peroxidase block, secondary antibody polymer, DAB, and Hematoxylin. Once completed, slides were 
removed from the stainer and rinsed for 5 minutes in tap water. Slides were dehydrated in increasing concentra-
tions of ethyl alcohol and xylene prior to permanent coverslipping in xylene based media.
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